 Exicure Inc NASDAQ: XCUR has reported interim results from Phase 1b2 trial evaluating cavrotolimod AST-008 in patients with advanced or metastatic solid tumors refractory to anti-PD-L1 therapy. The trial is assessing cavrotolimod in combination with Merck Co Incs NYSE: MRK Keytruda pembrolizumab or Sanofi SA NASDAQ: SNY - Regeneron Pharmaceuticals Incs NASDAQ: REGN Libtayo cemiplimab in two primary dose-expansion cohorts, one in Merkel cell carcinoma MCC and one in cutaneous squamous cell carcinoma CSCC, and three exploratory cohorts. 